Posted by Michael Wonder on 05 Jun 2019
Sierra announces momelotinib granted FDA fast track designation
5 June 2019 - Fast Track designation highlights the potential for momelotinib to address the significant unmet needs of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.
Sierra Oncology today announced that the U.S. FDA has granted fast track designation to momelotinib, a JAK1, JAK2 and ACVR1 inhibitor, for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.
